Carcinoma, Hepatocellular Clinical Trial
Official title:
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
Verified date | July 2019 |
Source | Rutgers, The State University of New Jersey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT). Remote ischemic conditioning will consist of 3 cycles of 5 minutes of lower limb ischemia induced via a mid-thigh pneumatic tourniquet, followed by 5 minutes of reperfusion. Interventions will take place after anesthesia induction but before surgery, at the completion of the procedure, and on the mornings of post-operative days 1-4.
Status | Completed |
Enrollment | 31 |
Est. completion date | December 31, 2017 |
Est. primary completion date | October 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adults (> 18 years of age) with acute and chronic liver failure requiring liver transplants or patients undergoing transplantation for hepatocellular carcinoma. - Both sexes - Written consent to participate in the study Exclusion Criteria: - < 18 years of age - Recipients of split livers - Retransplantation - Recipients of livers combined with other organs - Recipients of livers from cardiac death donors - Lower extremity amputees - History of peripheral vascular disease - Patients taking sulfonylurea anti-diabetic agents at the time of transplant - Patients taking nitrates at the time of transplant - Body mass index > 45 - Pregnant patients - Patients in whom complete lower extremity ischemia is not achieved despite maximum tourniquet inflation to 250 mmHg during the first intervention - Patients with lower extremity paralysis |
Country | Name | City | State |
---|---|---|---|
United States | Rutgers University - University Hospital | Newark | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Rutgers, The State University of New Jersey |
United States,
Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007 Sep 11;116(11 Suppl):I98-105. — View Citation
Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg. 2000 Aug;232(2):242-53. — View Citation
Bilgin-Freiert A, Dusick JR, Stein NR, Etchepare M, Vespa P, Gonzalez NR. Muscle microdialysis to confirm sublethal ischemia in the induction of remote ischemic preconditioning. Transl Stroke Res. 2012 Jun;3(2):266-72. doi: 10.1007/s12975-012-0153-1. Epub 2012 Apr 10. — View Citation
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. — View Citation
Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, Merion RM. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006 Apr;6(4):783-90. Erratum in: Am J Transplant. 2018 Dec;18(12):3085. — View Citation
Gonzalez NR, Hamilton R, Bilgin-Freiert A, Dusick J, Vespa P, Hu X, Asgari S. Cerebral hemodynamic and metabolic effects of remote ischemic preconditioning in patients with subarachnoid hemorrhage. Acta Neurochir Suppl. 2013;115:193-8. doi: 10.1007/978-3-7091-1192-5_36. — View Citation
Gracey DR, Divertie MB, Didier EP. Preoperative pulmonary preparation of patients with chronic obstructive pulmonary disease: a prospective study. Chest. 1979 Aug;76(2):123-9. — View Citation
Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, Chang CC, Kellum JA. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015 Jun;114(6):919-26. doi: 10.1093/bja/aeu556. Epub 2015 Feb 10. — View Citation
Huang CT, Lin HC, Chang SC, Lee WC. Pre-operative risk factors predict post-operative respiratory failure after liver transplantation. PLoS One. 2011;6(8):e22689. doi: 10.1371/journal.pone.0022689. Epub 2011 Aug 1. — View Citation
Koch S, Katsnelson M, Dong C, Perez-Pinzon M. Remote ischemic limb preconditioning after subarachnoid hemorrhage: a phase Ib study of safety and feasibility. Stroke. 2011 May;42(5):1387-91. doi: 10.1161/STROKEAHA.110.605840. Epub 2011 Mar 17. — View Citation
Kottenberg E, Thielmann M, Bergmann L, Heine T, Jakob H, Heusch G, Peters J. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand. 2012 Jan;56(1):30-8. doi: 10.1111/j.1399-6576.2011.02585.x. Epub 2011 Nov 21. — View Citation
Levesque E, Hoti E, Azoulay D, Honore I, Guignard B, Vibert E, Ichai P, Antoun F, Saliba F, Samuel D. Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. Transplantation. 2012 Sep 15;94(5):532-8. — View Citation
Li S, Ma C, Shao G, Esmail F, Hua Y, Jia L, Qin J, Ren C, Luo Y, Ding Y, Borlongan CV, Ji X. Safety and Feasibility of Remote Limb Ischemic Preconditioning in Patients With Unilateral Middle Cerebral Artery Stenosis and Healthy Volunteers. Cell Transplant. 2015;24(9):1901-11. doi: 10.3727/096368914X683520. Epub 2014 Jul 30. — View Citation
MacAllister R, Clayton T, Knight R, Robertson S, Nicholas J, Motwani M, Veighey K. REmote preconditioning for Protection Against Ischaemia–Reperfusion in renal transplantation (REPAIR): a multicentre, multinational, double-blind, factorial designed randomised controlled trial. Southampton (UK): NIHR Journals Library; 2015 May. — View Citation
McCafferty K, Forbes S, Thiemermann C, Yaqoob MM. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech. 2014 Dec;7(12):1321-33. doi: 10.1242/dmm.016741. Review. — View Citation
Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012 Oct 30;79(18):1853-61. doi: 10.1212/WNL.0b013e318271f76a. Epub 2012 Oct 3. — View Citation
Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091. — View Citation
Parikh A, Washburn KW, Matsuoka L, Pandit U, Kim JE, Almeda J, Mora-Esteves C, Halff G, Genyk Y, Holland B, Wilson DJ, Sher L, Koneru B. A multicenter study of 30 days complications after deceased donor liver transplantation in the model for end-stage liver disease score era. Liver Transpl. 2015 Sep;21(9):1160-8. doi: 10.1002/lt.24181. — View Citation
Przyklenk K, Whittaker P. Genesis of remote conditioning: action at a distance--'hypotheses non fingo'? J Cardiovasc Med (Hagerstown). 2013 Mar;14(3):180-6. doi: 10.2459/JCM.0b013e328358c8eb. Review. — View Citation
Rehni AK, Shri R, Singh M. Remote ischaemic preconditioning and prevention of cerebral injury. Indian J Exp Biol. 2007 Mar;45(3):247-52. — View Citation
Salvalaggio PR, Felga GE, Afonso RC, Ferraz-Neto BH. Early allograft dysfunction and liver transplant outcomes: a single center retrospective study. Transplant Proc. 2012 Oct;44(8):2449-51. doi: 10.1016/j.transproceed.2012.08.002. — View Citation
Section 2: AKI Definition. Kidney Int Suppl (2011). 2012 Mar;2(1):19-36. — View Citation
Svensson LG, Hess KR, Coselli JS, Safi HJ, Crawford ES. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991 Sep;14(3):271-82. — View Citation
Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review. J Surg Res. 2008 Dec;150(2):304-30. doi: 10.1016/j.jss.2007.12.747. Epub 2008 Jan 22. Review. — View Citation
Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S, Zahn PK, Wolf B, Goebel U, Schwer CI, Rosenberger P, Haeberle H, Görlich D, Kellum JA, Meersch M; RenalRIPC Investigators. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA. 2015 Jun 2;313(21):2133-41. doi: 10.1001/jama.2015.4189. — View Citation
* Note: There are 25 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Completing Entire Intervention Protocol | Proportion of enrolled liver recipients that complete all 6 remote ischemic conditioning (RIC) interventions. | Pre-op - Post-op day 4 | |
Secondary | Intervention-related Pain Score | Median intervention-related pain score during each of the post-operative interventions, in extubated patients who are able to communicate. Using the Numerical Rating Scale (NRS, Ferrieira-Valente MA PAIN Volume 152, 2011), patients were asked to rate their pain following the intervention on a scale of 0-10 with 0 being no pain experienced to 10 as the maximum pain felt. | Post-op days 1-4 | |
Secondary | Withdrawal of Consent Due to Pain | - Withdrawal of consent due to discomfort/pain in the lower extremity | Pre-op - Post-op day 7 | |
Secondary | Percentage of Participants Who Developed Early Allograft Dysfunction (EAD) | Percentage of participants who developed Early Allograft Dysfunction (EAD) which is defined as: Aspartate Transaminase (AST) or Alanine Transaminase (ALT)> 2,000 U/L at any point within the first seven post-transplant days, or Total Bilirubin (TB) > 10 mg/dL on postoperative day 7,or International Normalized Ratio (INR)> 1.6 on postoperative day 7. |
Post-op days 0-7 | |
Secondary | Percentage of Participants Who Developed Prolonged Respiratory Insufficiency (PRI) | Percentage of Participants who developed Prolonged Respiratory Insufficiency (PRI) defined as: Ventilator support for >2 postoperative days after transplant, or Reintubation after extubation, within 7 days of transplant. Patients who require brief re-intubation for an endoscopic, radiologic, or surgical procedure would not be considered to have PRI if they are extubated within 2 days of the end of the procedure. |
Post-op days 0-7 | |
Secondary | Percentage of Participants Who Developed Acute Kidney Injury (AKI) Stages 2 or 3 | Percentage of participants who developed Acute Kidney Injury (AKI) Based on Kidney Disease - Improving Global Outcomes (KDIGO) criteria, AKI criteria are: Stage 2: - 2.0-2.9 fold rise in serum creatinine from baseline Stage 3: > 3.0 fold rise in serum creatinine from baseline, or Serum creatinine of > 4.0 mg/dL, with an acute (<48 hours) increase of 0.3 mg/dL in serum creatinine or subacute (< 7 days) increase in serum creatinine of 0.5 mg/dL, or Initiation of renal replacement therapy. |
Post-op days 0-7 | |
Secondary | Time to Dialysis Discontinuation | In patients who are receiving dialysis pre-op, time to discontinuation of dialysis, if occurring within 90 days of transplantation. | Post-op days 0-90 | |
Secondary | Presence of Clavien-Dindo Grade IIIb or Higher Complications | Percentage of patients with Clavien-Dindo >/= grade III b complications (Dindo D, Demartines N, Clavien P, Annals of Surgery 2004). The Clavien-Dindo Complications grade ranges from Grade I (Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside) to Grade V (Death). Grade IIIb would be any intervention requiring general anesthesia. |
Post-op days 0-30 | |
Secondary | Clavien-Dindo Grade IIIb or Higher - Number of Complications | In patients with Clavien-Dindo >/= IIIb complications, number of such complications per patient. | Post-op days 0-30 | |
Secondary | Intensive Care Unit (ICU) Length of Stay (LOS) | Number of days in ICU post-transplant. Starting at post-op day 0 and ending on the calendar date that the patient is transferred out of ICU, dies, or post-op day 90, whichever is soonest. | Post-op days 0 up to 90 days | |
Secondary | Hospital LOS | Number of days in hospital post-transplant. Starting at post-op day 0 and ending on the calendar date that the patient is leaves the hospital, dies, or post-op day 90, whichever is soonest. | Post-op days 0 up to 90 days | |
Secondary | Liver Allograft Survival | Percentage of patients with functioning allograft at 90 days post-transplant | Post-op day 90 | |
Secondary | Patient Survival | Percentage of patients alive at 90 days post-transplant | Post-op day 90 | |
Secondary | Number of Subjects Not Completing Intervention Protocol | Number of subjects that received fewer than 6 interventions,. | Pre-op - Post-op day 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03289533 -
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
|
Phase 1 | |
Terminated |
NCT01141478 -
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
|
N/A | |
Recruiting |
NCT05580835 -
PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
Active, not recruiting |
NCT05389527 -
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04560751 -
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
|
||
Withdrawn |
NCT02939807 -
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT01915602 -
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
Recruiting |
NCT02403544 -
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT01897038 -
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
Terminated |
NCT01337492 -
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|
Phase 0 | |
Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
Completed |
NCT01003015 -
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00559455 -
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT00384800 -
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
Terminated |
NCT00582400 -
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
|
Phase 2 | |
Completed |
NCT00056992 -
Testing of ADI-PEG in Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT02859324 -
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
|
Phase 1/Phase 2 | |
Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A |